Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 152741, 5 pages
http://dx.doi.org/10.1155/2015/152741
Research Article

Potential Use of Interleukin-10 Blockade as a Therapeutic Strategy in Human Cutaneous Leishmaniasis

1Laboratory of Immunology, Federal University of Triângulo Mineiro, 38025-180 Uberaba, MG, Brazil
2Human Immunology Research and Education Group-GEPIH, Technical Health School, Federal University of Paraíba, 58051-900 João Pessoa, PB, Brazil
3Laboratory of Parasitology Mycology, INSERM U399, Faculty of Medicine, 27 boulevard Jean Moulin, 13385 Marseille Cedex 05, France
4Infectious Diseases Division, Federal University of Triângulo Mineiro, 38025-180 Uberaba, MG, Brazil

Received 6 November 2014; Revised 29 December 2014; Accepted 31 December 2014

Academic Editor: Oguz Kul

Copyright © 2015 Lucio Roberto Castellano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Interleukin-10 overproduction has been associated with worse prognosis in human cutaneous leishmaniasis, while IFN-γ-dependent responses are associated with parasite killing and host protection. Innovative strategies are needed to overcome therapeutic failure observed in endemic areas. The use of monoclonal antibody-based immunotherapy targeting IL-10 cytokine was evaluated here. Partial IL-10 blockade in Leishmania braziliensis whole soluble antigen-stimulated cells from endemic area CL patients with active or healed lesions and asymptomatic controls was evaluated. Overall decrease in IL-10, IL-4, and TNF-α production was observed in all groups of subjects. Only patients with active lesions still produced some levels of TNF-α after anti-IL-10 stimulation in association with Leishmania antigens. Moreover, this strategy showed limited modulatory effects on IFN-γ-dependent chemokine CXCL10 production. Results suggest the potential immunotherapeutic use of partial IL-10 blockade in localized cutaneous leishmaniasis.